Pulmonary gemcitabine delivery for treating lung cancer: Pharmacokinetics and acute lung injury aspects in animals

Canadian Journal of Physiology and Pharmacology

Volumn 86, Issue 5, 2008, Pages 288-298

  Min, Rui ^a   Li, Ting ^a   Du, Ju ^a   Zhang, Yan ^a   Guo, Jia ^a   Lu, Wan Liang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Acute lung injury; Gemcitabine; Lung cancer; Pharmacokinetics; Pulmonary delivery

Indexed keywords

GEMCITABINE; LIPOPOLYSACCHARIDE; PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; HISTOPATHOLOGY; LUNG CANCER; LUNG LAVAGE; LUNG WEIGHT; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY TESTING;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL AVAILABILITY; BRONCHOALVEOLAR LAVAGE FLUID; DEOXYCYTIDINE; INJECTIONS, INTRAVENOUS; INTUBATION, GASTROINTESTINAL; INTUBATION, INTRATRACHEAL; LUNG; MALE; PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY DISTRESS SYNDROME, ADULT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 43949144185     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y08-039     Document Type: Article

References (44)

1. Abratt, R.P., Bezwoda, W.R., Falkson, G., Goedhals, L., Hacking, D., and Rugg, T.A. 1994. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J. Clin. Oncol. 12: 1535-1540. PMID:8040664.
2. Anderson, P.J. 2001. Delivery options and devices for aerosolized therapeutics. Chest, 120: 89-93. doi:10.1378/chest.120.3_suppl.89S.
3. Bhatia, M., and Moochhala, S. 2004. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J. Pathol. 202: 145-156. doi:10.1002/path.1491. PMID:14743496.
4. Boccia, R., Anné, P.R., Bourhis, J., Brizel, D., Daly, C., Holloway, N., 3rd, et al. 2004. Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP). Int. J. Radiat. Oncol. Biol. Phys. 60: 302-309. doi:10.1016/j.ijrobp.2004.07.103. PMID:15337569.
5. Bouffard, D.Y., Laliberté, J., and Momparler, R.L. 1993. Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem. Pharmacol. 45: 1857-1861. doi:10.1016/0006-2952(93)90444-2. PMID:8494545.
6. Brain, J.D., Knudson, D.E., Sorokin, S.P., and Davis, M.A. 1976. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ. Res. 11: 13-33. doi:10.1016/0013-9351(76) 90107-9. PMID:1253768.
7. Brocklebank, D., Ram, F., Wright, J., Barry, P., Cates, C., Davies, L., et al. 2001. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol. Assess. 5: 1-149. PMID:11701099.
8. Byron, P.R., and Patton, J.S. 1994. Drug delivery via the respiratory tract. J. Aerosol Med. 7: 49-75. PMID:10147058.
9. Chen, H., Zhang, L., Jin, Z., Jin, E., Fujiwara, M., Ghazizadeh, M., et al. 2007. Anti-apoptotic PTD-FNK protein suppresses lipopolysaccharide-induced acute lung injury in rats. Exp. Mol. Pathol. 83: 377-384. doi:10.1016/j.yexmp.2007.08.016. PMID:17959170.
10. Cleland, J.L., Daugherty, A., and Mrsny, R. 2001. Emerging protein delivery methods. Curr. Opin. Biotechnol. 12: 212-219. doi:10.1016/S0958-1669(00)00202-0. PMID:11287240.
11. Du Bois, A., Kommoss, F.G., Pfisterer, J., Lück, H.J., and Meerpohl, H.G. 1996. Paclitaxel-induced "recall" soft tissue ulcerations occurring at the site of previous subcutaneous administration of paclitaxel in low doses. Gynecol. Oncol. 60: 94-96. doi:10.1006/gyno.1996.0017. PMID:8557235.
12. Edwards, D.A., Hanes, J., Caponetti, G., Hrkach, J., Ben-Jebria, A., Eskew, M.L., et al. 1997. Large porous particles for pulmonary drug delivery. Science, 276: 1868-1871. doi:10.1126/science.276.5320.1868. PMID:9188534.
13. Fan, J., Marshall, J.C., Jimenez, M., Shek, P.N., Zagorski, J., and Rotstein, O.D. 1998. Hemorrhagic shock primes for increased expression of cytokine-induced neutrophil chemoattractant in the lung: role in pulmonary inflammation following lipopolysaccharide. J. Immunol. 161: 440-447. PMID:9647254.
14. Freise, K.J., and Martín-Jiménez, T. 2006. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics. J. Vet. Pharmacol. Ther. 29: 137-145. doi:10.1111/j.1365-2885.2006.00725.x. PMID:16515668.
15. Gridelli, C., Manegold, C., Mali, P., Reck, M., Portalone, L., Castelnau, O., et al. 2004. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. Eur. J. Cancer, 40: 2424-2431. doi:10.1016/j.ejca.2004.07.028. PMID:15519515.
16. Hsieh, S.C., Lu, C.C., Horng, Y.T., Soo, P.C., Chang, Y.L., Tsai, Y.H., et al. 2007. The bacterial metabolite 2,3-butanediol ameliorates endotoxin-induced acute lung injury in rats. Microbes Infect. 9: 1402-1409. doi:10.1016/j.micinf.2007.07.004. PMID:17913548.
17. Immordino, M.L., Brusa, P., Rocco, F., Arpicco, S., Ceruti, M., and Cattel, L. 2004. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs. J. Control. Release, 100: 331-346. doi:10.1016/j.jconrel.2004.09.001. PMID:15567500.
18. Jassem, J., Karnicka-Młodkowska, H., van Pottelsberghe, C., van Glabbeke, M., Noseda, M.A., Ardizzoni, A., et al. 1993. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur. J. Cancer, 29A: 1720-1722. doi:10.1016/0959-8049(93)90112-S. PMID:8398301.
19. Jendle, J.H., and Karlberg, B.E. 1996. Intrapulmonary administration of insulin to healthy volunteers. J. Intern. Med. 240: 93-98. doi:10.1046/j.1365-2796.1996.502836000.x. PMID:8810935.
20. Kim, J.H., Lee, D.H., Shin, H.C., Kwon, J.H., Jung, J.Y., Kim, H.J., et al. 2006. A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer. Lung Cancer, 54: 57-62. doi:10.1016/j.lungcan.2006.06.013. PMID:16884818.
21. Kirstein, M.N., Hassan, I., Guire, D.E., Weller, D.R., Dagit, J.W., Fisher, J.E., et al. 2006. High-performance liquid chromatographic method for the determination of gemcitabine and 2′,2′-difluorodeoxyuridine in plasma and tissue culture media. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 835: 136-142. doi:10.1016/j.jchromb.2006.03.023. PMID:16584929.
22. Kobayashi, S., Kondo, S., and Juni, K. 1994. Study on pulmonary delivery of salmon calcitonin in rats effects of protease inhibitors and absorption enhancers. Pharm. Res. 11: 1239-1243. doi:10.1023/A:1018926007902. PMID:7816750.
23. Kosmas, C., Tsavaris, N., Mylonakis, N., and Kalofonos, H.P. 2003. An overview of current results with the gemcitabine and docetaxel combination as initial and salvage chemotherapy regimen in advanced non-small cell lung cancer. Crit. Rev. Oncol. Hematol. 45: 265-275. doi:10.1016/S1040-8428(02)00081- 1. PMID:12633839.
24. Le Chevalier, T. 1996. Single-agent activity of gemcitabine in advanced non-small cell lung cancer. Semin. Oncol. 23(Suppl 10): 36-42. PMID:8893880.
25. Lichtman, S.M., and Villani, G. 2000. Chemotherapy in the elderly: pharmacologic considerations. Cancer Control, 7: 548-556. PMID:11088063.
26. Linskens, R.K., Golding, R.P., van Groeningen, C.J., and Giaccone, G. 2000. Severe acute lung injury induced by gemcitabine. Neth. J. Med. 56: 232-235. doi:10.1016/S0300-2977(00)00029-2. PMID:10821980.
27. Liu, G., Franssen, E., Fitch, M.I., and Warner, E. 1997. Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol. 15: 110-115. PMID:8996131.
28. Matthay, M.A., Zimmerman, G.A., Esmon, C., Bhattacharya, J., Coller, B., Doerschuk, C.M., et al. 2003. Future research directions in acute lung injury: summary of a national heart, lung, and blood institute working group. Am. J. Respir. Crit. Care Med. 167: 1027-1035. doi:10.1164/rccm.200208-966WS. PMID:12663342.
29. Myhren, F., Borretzen, B., Dalen, A., and Sandvold, M. 1998. Gemcitabine derivatives. WO 98/32762.
30. Novello, S., and Le Chevalier, T. 2003. Chemotherapy for non-small-cell lung cancer. Part 1: Early-stage disease. Oncology, 17: 357-364. [Williston Park.] PMID:12661267.
31. O'Hagan, D.T., and Illum, L. 1990. Absorption of peptides and proteins from the respiratory tract and the potential for development of locally administered vaccine. Crit. Rev. Ther. Drug Carrier Syst. 7: 35-97. PMID:2257636.
32. Patton, J.S. 1996. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev. 19: 3-36. doi:10.1016/0169-409X(95)00113-L.
33. Pittet, J.F., Mackersie, R.C., Martin, T.R., and Matthay, M.A. 1997. Biological markers of acute lung injury: prognostic and pathogenetic significance. Am. J. Respir. Crit. Care Med. 155: 1187-1205. PMID:9105054.
34. Qiao, W.B., Wang, R.Z., Wang, C.B., Zhao, Y.H., and You, Q.S. 2006. Experimental study on gemcitabine increase of radiation-induced pulmonary injury in mice. Chin. J. Radiat. Oncol. 15: 124-128.
35. Quinton, L.J., Nelson, S., Zhang, P., Boé, D.M., Happel, K.I., Pan, W., et al. 2004. Selective transport of cytokine-induced neutrophil chemoattractant from the lung to the blood facilitates pulmonary neutrophil recruitment. Am. J. Physiol. Lung Cell. Mol. Physiol. 286: L465-L472. doi:10.1152/ajplung.00153.2003. PMID:14617513.
36. Redl, H., Bahrami, S., Schlag, G., and Traber, D.L. 1993. Clinical detection of LPS and animal models of endotoxemia. Immunobiology, 187: 330-345. PMID:8330902.
37. Repine, J.E., and Beehler, C.J. 1991. Neutrophils and adult respiratory distress syndrome: two interlocking perspectives in 1991. Am. Rev. Respir. Dis. 144: 251-252. PMID:1859047.
38. Sakagami, M. 2006. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv. Drug Deliv. Rev. 58: 1030-1060. doi:10.1016/j.addr.2006. 07.012. PMID:17010473.
39. Sandler, A., and Ettinger, D.S. 1999. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. Oncologist, 4: 241-251. PMID:10394591.
40. Shen, Z., Zhang, Q., Wei, S., and Nagai, T. 1999. Proteolytic enzymes as a limitation for pulmonary absorption of insulin: in vitro and in vivo investigations. Int. J. Pharm. 192: 115-121. doi:10.1016/S0378-5173(99) 00295-1. PMID:10567743.
41. Shipley, L.A., Brown, T.J., Cornpropst, J.D., Hamilton, M., Daniels, W.D., and Culp, H.W. 1992. Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab. Dispos. 20: 849-855. PMID:1362937.
42. Smith, I.J., and Parry-Billings, M. 2003. The inhalers of the future? A review of dry powder devices on the market today. Pulm. Pharmacol. Ther. 16: 79-95. doi:10.1016/S1094-5539(02) 00147-5. PMID:12670777.
43. Wang, X.Y., Wu, S.Y., Li, S.A., and Mao, D.H. 2004. The method of tracheal intubation under direct vision in rats. Shanghai. Lab. Anim. Sci. 24: 107-108.
44. Weksler, B., Ng, B., Lenert, J., and Burt, M. 1994. A simplified method for endotracheal intubation in the rat. J. Appl. Physiol. 76: 1823-1825. PMID:8045865.